These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 17848099)

  • 1. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
    Thomson JM; Distler AM; Bonomo RA
    Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.
    Swarén P; Golemi D; Cabantous S; Bulychev A; Maveyraud L; Mobashery S; Samama JP
    Biochemistry; 1999 Jul; 38(30):9570-6. PubMed ID: 10423234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.
    Li M; Conklin BC; Taracila MA; Hutton RA; Skalweit MJ
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5678-86. PubMed ID: 22908166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
    Papp-Wallace KM; Bethel CR; Distler AM; Kasuboski C; Taracila M; Bonomo RA
    Antimicrob Agents Chemother; 2010 Feb; 54(2):890-7. PubMed ID: 20008772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance.
    Thomson JM; Distler AM; Prati F; Bonomo RA
    J Biol Chem; 2006 Sep; 281(36):26734-44. PubMed ID: 16803899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase. Insights into the mechanism of inhibition.
    Sulton D; Pagan-Rodriguez D; Zhou X; Liu Y; Hujer AM; Bethel CR; Helfand MS; Thomson JM; Anderson VE; Buynak JD; Ng LM; Bonomo RA
    J Biol Chem; 2005 Oct; 280(42):35528-36. PubMed ID: 15987690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains.
    Paniagua GL; Monroy E; García O; Vaca S
    Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.
    Lin S; Thomas M; Shlaes DM; Rudin SD; Knox JR; Anderson V; Bonomo RA
    Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):395-400. PubMed ID: 9735103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.
    Drawz SM; Bethel CR; Hujer KM; Hurless KN; Distler AM; Caselli E; Prati F; Bonomo RA
    Biochemistry; 2009 Jun; 48(21):4557-66. PubMed ID: 19351161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
    Nord CE
    J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
    [No Abstract]   [Full Text] [Related]  

  • 12. beta-Lactam resistance phenotype determination in Escherichia coli isolates from University Malaya Medical Centre.
    Wong JS; Mohd Azri ZA; Subramaniam G; Ho SE; Palasubramaniam S; Navaratnam P
    Malays J Pathol; 2003 Dec; 25(2):113-9. PubMed ID: 16196367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
    Bethel CR; Taracila M; Shyr T; Thomson JM; Distler AM; Hujer KM; Hujer AM; Endimiani A; Papp-Wallace K; Bonnet R; Bonomo RA
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3465-75. PubMed ID: 21555770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
    Helfand MS; Bethel CR; Hujer AM; Hujer KM; Anderson VE; Bonomo RA
    J Biol Chem; 2003 Dec; 278(52):52724-9. PubMed ID: 14534312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
    Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
    J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of in vitro susceptibility testing results for amoxicillin-clavulanate and ampicillin-sulbactam using a panel of beta-lactamase-producing Enterobacteriaceae.
    Siu LK; Cheng WL; Ho PL; Ng WS; Chau PY; Lo JY
    APMIS; 1998 Sep; 106(9):917-20. PubMed ID: 9808419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
    Helfand MS; Totir MA; Carey MP; Hujer AM; Bonomo RA; Carey PR
    Biochemistry; 2003 Nov; 42(46):13386-92. PubMed ID: 14621983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OHIO-1 beta-lactamase mutants: the Arg244Ser mutant and resistance to beta-lactams and beta-lactamase inhibitors.
    Lin S; Thomas M; Mark S; Anderson V; Bonomo RA
    Biochim Biophys Acta; 1999 Jun; 1432(1):125-36. PubMed ID: 10366735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperproduction of inhibitor-susceptible TEM beta-lactamase is responsible for resistance of Serratia marcescens to beta-lactam-beta-lactamase inhibitor combinations.
    Zhao WH; Hu ZQ; Chen G; Ito R; Shimamura T
    Chemotherapy; 2008; 54(1):31-7. PubMed ID: 18063864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.